Book contents
- Frontmatter
- Contents
- Preface
- Contributors
- Part I Clinical Syndromes – General
- Part II Clinical Syndromes – Head and Neck
- Part III Clinical Syndromes – Eye
- Part IV Clinical Syndromes – Skin and Lymph Nodes
- Part V Clinical Syndromes – Respiratory Tract
- Part VI Clinical Syndromes – Heart and Blood Vessels
- Part VII Clinical Syndromes – Gastrointestinal Tract, Liver, and Abdomen
- Part VIII Clinical Syndromes – Genitourinary Tract
- Part IX Clinical Syndromes – Musculoskeletal System
- Part X Clinical Syndromes – Neurologic System
- Part XI The Susceptible Host
- Part XII HIV
- Part XIII Nosocomial Infection
- Part XIV Infections Related to Surgery and Trauma
- Part XV Prevention of Infection
- Part XVI Travel and Recreation
- Part XVII Bioterrorism
- Part XVIII Specific Organisms – Bacteria
- 121 Actinomycosis
- 122 Anaerobic Infections
- 123 Anthrax and Other Bacillus Species
- 124 Bartonellosis (Carrión's Disease)
- 125 Cat Scratch Disease and Other Bartonella Infections
- 126 Bordetella
- 127 Moraxella (Branhamella) Catarrhalis
- 128 Brucellosis
- 129 Campylobacter
- 130 Clostridia
- 131 Corynebacteria
- 132 Enterobacteriaceae
- 133 Enterococcus
- 134 Erysipelothrix
- 135 HACEK
- 136 Helicobacter Pylori
- 137 Gonococcus: Neisseria Gonorrhoeae
- 138 Haemophilus
- 139 Legionellosis
- 140 Leprosy
- 141 Meningococcus and Miscellaneous Neisseriae
- 142 Listeria
- 143 Nocardia
- 144 Pasteurella Multocida
- 145 Pneumococcus
- 146 Pseudomonas, Stenotrophomonas, and Burkholderia
- 147 Rat-Bite Fevers
- 148 Salmonella
- 149 Staphylococcus
- 150 Streptococcus Groups A, B, C, D, and G
- 151 Viridans Streptococci
- 152 Poststreptococcal Immunologic Complications
- 153 Shigella
- 154 Tularemia
- 155 Tuberculosis
- 156 Nontuberculous Mycobacteria
- 157 Vibrios
- 158 Yersinia
- 159 Miscellaneous Gram-Positive Organisms
- 160 Miscellaneous Gram-Negative Organisms
- Part XIX Specific Organisms – Spirochetes
- Part XX Specific Organisms – Mycoplasma and Chlamydia
- Part XXI Specific Organisms – Rickettsia, Ehrlichia, and Anaplasma
- Part XXII Specific Organisms – Fungi
- Part XXIII Specific Organisms – Viruses
- Part XXIV Specific Organisms – Parasites
- Part XXV Antimicrobial Therapy – General Considerations
- Index
141 - Meningococcus and Miscellaneous Neisseriae
from Part XVIII - Specific Organisms – Bacteria
Published online by Cambridge University Press: 05 March 2013
- Frontmatter
- Contents
- Preface
- Contributors
- Part I Clinical Syndromes – General
- Part II Clinical Syndromes – Head and Neck
- Part III Clinical Syndromes – Eye
- Part IV Clinical Syndromes – Skin and Lymph Nodes
- Part V Clinical Syndromes – Respiratory Tract
- Part VI Clinical Syndromes – Heart and Blood Vessels
- Part VII Clinical Syndromes – Gastrointestinal Tract, Liver, and Abdomen
- Part VIII Clinical Syndromes – Genitourinary Tract
- Part IX Clinical Syndromes – Musculoskeletal System
- Part X Clinical Syndromes – Neurologic System
- Part XI The Susceptible Host
- Part XII HIV
- Part XIII Nosocomial Infection
- Part XIV Infections Related to Surgery and Trauma
- Part XV Prevention of Infection
- Part XVI Travel and Recreation
- Part XVII Bioterrorism
- Part XVIII Specific Organisms – Bacteria
- 121 Actinomycosis
- 122 Anaerobic Infections
- 123 Anthrax and Other Bacillus Species
- 124 Bartonellosis (Carrión's Disease)
- 125 Cat Scratch Disease and Other Bartonella Infections
- 126 Bordetella
- 127 Moraxella (Branhamella) Catarrhalis
- 128 Brucellosis
- 129 Campylobacter
- 130 Clostridia
- 131 Corynebacteria
- 132 Enterobacteriaceae
- 133 Enterococcus
- 134 Erysipelothrix
- 135 HACEK
- 136 Helicobacter Pylori
- 137 Gonococcus: Neisseria Gonorrhoeae
- 138 Haemophilus
- 139 Legionellosis
- 140 Leprosy
- 141 Meningococcus and Miscellaneous Neisseriae
- 142 Listeria
- 143 Nocardia
- 144 Pasteurella Multocida
- 145 Pneumococcus
- 146 Pseudomonas, Stenotrophomonas, and Burkholderia
- 147 Rat-Bite Fevers
- 148 Salmonella
- 149 Staphylococcus
- 150 Streptococcus Groups A, B, C, D, and G
- 151 Viridans Streptococci
- 152 Poststreptococcal Immunologic Complications
- 153 Shigella
- 154 Tularemia
- 155 Tuberculosis
- 156 Nontuberculous Mycobacteria
- 157 Vibrios
- 158 Yersinia
- 159 Miscellaneous Gram-Positive Organisms
- 160 Miscellaneous Gram-Negative Organisms
- Part XIX Specific Organisms – Spirochetes
- Part XX Specific Organisms – Mycoplasma and Chlamydia
- Part XXI Specific Organisms – Rickettsia, Ehrlichia, and Anaplasma
- Part XXII Specific Organisms – Fungi
- Part XXIII Specific Organisms – Viruses
- Part XXIV Specific Organisms – Parasites
- Part XXV Antimicrobial Therapy – General Considerations
- Index
Summary
MENINGOCOCCAL INFECTION
Meningococcal infection, first recognized nearly 2 centuries ago as epidemic cerebrospinal fever, occurs worldwide as sporadic, endemic, and epidemic cases. Worldwide, most cases are caused by serogroups A and C, whereas in the United States, serogroups B and Y predominate (see “Culture and Laboratory Findings”). Humans are the only natural host for the bacteria. Transmission of the organism occurs from person to person by direct contact with contaminated respiratory secretions or airborne droplets with subsequent colonization of the nasopharynx. Nasopharyngeal carriage approximates 5% to 15% in nonepidemic periods but may approach 50% to 95% during epidemics, especially serogroup A epidemics. The carriage rate is also increased when there is crowding, such as in military barracks, dormitories, prisons, convocations, and sporting events. The oropharyngeal and nasopharyngeal carriage may persist for several weeks to several months. Sexual transmission of meningococci in women and homo sexual men may result in anogenital carriage. Most cases of disease (eg, bacteremia, meningitis) occur in children between 6 months and 5 years of age. With few exceptions, invasive meningococci have a polysaccharide capsule that forms the basis for serogrouping of strains. Invasive disease occurs almost exclusively in persons who lack specific antimeningococcal antibody to the colonizing meningococcal strain. Individuals with complement component deficiencies are at an increased risk for developing invasive meningococcal infections because their serum loses the ability of complement-antibody mediated lysis of the bacteria.
- Type
- Chapter
- Information
- Clinical Infectious Disease , pp. 997 - 1004Publisher: Cambridge University PressPrint publication year: 2008